Document is current
Any future updates will be listed below
-
Authors
Zhang, Xuqing
Luo, Mengyao
Dastagir, Shamael R.
Nixon, Mellissa
Khamhoung, Annie https://orcid.org/0000-0003-1679-7125
Schmidt, Andrea
Lee, Albert
Subbiah, Naren
McLaughlin, Douglas C.
Moore, Christopher L.
Gribble, Mary
Bayhi, Nicholas
Amin, Viral
Pepi, Ryan
Pawar, Sneha
Lyford, Timothy J.
Soman, Vikram
Mellen, Jennifer
Carpenter, Christopher L.
Turka, Laurence A. https://orcid.org/0000-0003-2104-6967
Wickham, Thomas J.
Chen, Tiffany F. https://orcid.org/0000-0002-8089-1143
- License Information
-
More Information
Article History
Received: 23 February 2021
Accepted: 31 March 2021
First Online: 11 May 2021
Competing interests
: All authors have or had employment and equity ownership in Rubius Therapeutics during conduct of research or currently. M.L. is currently an employee of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA. M.N. is currently an employee of Merck & Co., Inc., Boston, Massachusetts, USA. A.K. and C.L.C. are currently employees of Catamaran Bio, Inc., Cambridge, Massachusetts, USA. A.L. is currently an employee of Kymera Therapeutics, Inc., Watertown, Massachusetts, USA. D.C.M. is currently an employee of MoMa Therapeutics, Inc., Cambridge, Massachusetts, USA. L.A.T is a scientific founder and holds equity in Rheos Medicines, Inc., Cambridge, Massachusetts, USA, and is a scientific advisory board member and holds equity in Solid BioSciences, Inc., Cambridge, Massachusetts, USA. T.J.W. is currently an employee of GentiBio, Inc., Boston, Massachusetts, USA. The trademarks of Rubius Therapeutics, Inc. – including Red Cell Therapeutics, RCT and RTX, are owned by Rubius Therapeutics and may only be used with its express permission.
